Ocular Therapeutix Inc. - notizie pubblicate 213 - letture 2.932
OCULAR THERAPEUTIX INC.
Material Event - Form 8-K
Item 8.01 other events. on march 28, 2024, ocular therapeutix, inc. modified its employment agreement with peter kaiser, m.d., its medical director, to eliminate his 50% service re ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
Bedford, mass., march 26, 2024 (globe newswire) -- ocular therapeutix, inc. (nasdaq:ocul, "ocular", the "company"), a biopharmaceutical company committed to enh ...
OCULAR THERAPEUTIX INC.
Automatic Shelf Registration Statement - Form S-3ASR
Tm249621-1_s3asr - none - 3.1093776s table of contents as filed with the securities and exchange commission on march 25, 2024 registration no. 333- united states securities and exc ...
OCULAR THERAPEUTIX INC.
Initial Registration Statement for Employee Benefit Plan - Form S-8
As filed with the securities and exchange commission on march 11, 2024 registration no. 333-_____ united states securities and exchange commission washington, d.c. 20549 form s-8 r ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results - Form 8-K
Ocular therapeutix™ reports fourth quarter and full year 2023 results leadership appointments move ocular towards being a leader in retinal care screening underway in axpaxli™ ...
OCULAR THERAPEUTIX INC.
Annual Report for Fiscal Year Ending December 31, 2023 (Form 10-K)
Table of contents united states securities and exchange commission washington, d.c. 20549 form 10-k (mark one) ☒annual report pursuant to section 13 or 15(d) of the securities ex ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
Leadership appointments move ocular towards being a leader in retinal care screening underway in axpaxli™ phase 3 sol-1 trial for wet amd topline clinical data for axpaxli in dia ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
Bedford, mass., march 05, 2024 (globe newswire) -- ocular therapeutix, inc. (nasdaq:ocul, the "company"), a biopharmaceutical company committed to enhancing people's visi ...
OCULAR THERAPEUTIX INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
OCULAR THERAPEUTIX INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
OCULAR THERAPEUTIX INC.
Initial Statement of Beneficial Ownership - Form 3
Ownership submission form 3 united states securities and exchange commission washington, d.c. 20549initial statement of beneficial ownership of securities filed pursuant to section ...
OCULAR THERAPEUTIX INC.
Initial Statement of Beneficial Ownership - Form 3
Ownership submission form 3 united states securities and exchange commission washington, d.c. 20549initial statement of beneficial ownership of securities filed pursuant to section ...
OCULAR THERAPEUTIX INC.
Initial Registration Statement for Employee Benefit Plan - Form S-8
As filed with the securities and exchange commission on february 22, 2024 registration no. 333-_____ united states securities and exchange commission washington, d.c. 20549 form s- ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer
Bedford, mass., feb. 22, 2024 (globe newswire) -- ocular therapeutix, inc. (nasdaq:ocul) ("ocular"), a biopharmaceutical company committed to enhancing people's vision an ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement
Bedford, mass., feb. 22, 2024 (globe newswire) -- ocular therapeutix, inc. (nasdaq:ocul) (the "company"), a biopharmaceutical company committed to enhancing people's visi ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti